Innovative and Forward-Looking Strategies to Accelerate Clinical Research During a Public Health Emergency
The unprecedented disruptions brought on by the COVID-19 pandemic has underscored the global need to establish preparatory and response policies to minimize the social and economic burden of a future pandemic. The World Health Organization (WHO), the US Department of Health and Human Services (HHS), the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), the White House, European Commission and other governing bodies have implemented pandemic preparedness action plans. These plans outline processes for increased surveillance and to protect supply chains and manufacturing. This forward-thinking approach to the preservation of public health will be vital in addressing a future pandemic.
Just as public health leaders have outlined plans to prepare for the next pandemic, pharmaceutical developers must also be prepared to meet the challenges presented during global health emergencies. When faced with a rapidly evolving public health emergency, bringing medical countermeasures to market is complex. Developers should choose an innovative and experienced CRO (Contract Research Organization) partner who is strategic and forward-looking in their approach. The right partner will have an established pandemic preparedness plan already in place.